Track A Orientation Guido Silvestri, M.D. Track A Co-Chair www.ias2011.org.

Slides:



Advertisements
Similar presentations
Unit 6 Diagnosis & Follow-up of HIV Infection
Advertisements

1 Workshop on the immunological basis of vaccine efficacy Vaccine and Infectious Disease Institute December 14, 2009 Ira M. Longini, Jr. Center for Statistical.
Adriana Weinberg, MD University of Colorado Denver.
Controversies in HIV Cure Research Debate 1. Is there ongoing replication under HAART? Mario Stevenson and Frank Maldarelli Moderator: Steve Deeks.
What can we learn from diverse spectrum of HIV/SIV infections? Françoise BARRÉ-SINOUSSI Regulation of Retroviral Infections Unit Department of Virology.
(DO QUIZ FIRST) Section 3 Viruses
Viruses.
Strategies for Targeting and Eradicating the HIV Reservoir
Biology in Your World Section 1.2.
Blocviroc – an innovative treatment for HIV/AIDS Steve English Development Head, Antivirals.
HIV Science Update from Rome to Addis : Basic Science Coumba Toure Kane Dakar University Senegal.
Future directions in HIV basic science research The hunt for a cure.
HIV/AIDS Isabelle Récaborde Dr. Frigon Chemistry SL – Block F Option - Medicine and Drugs.
Lesson 4 Treatment for HIV / AIDS
Track B : Conference Orientation Session Papa Salif Sow MD, MSc Co-Chair Track B IAS Rome July 2011.
Infection Control for Medical Asepsis
IAS 2012 feedback: UK Consortium: September 2012 IAS 2012 Feedback: New findings, better drugs and the goal of a cure Simon Collins HIV.
HIV Cellular Pathogenesis III
Biomedical Technology Unit Treatment for heart disease Heart-lung machine Treatment for cancer Treatment for diabetes Bone marrow transplants.
Studies of HIV Eradication: a Case for Using NHP Models Guido Silvestri, MD Yerkes National Primate Research Center Emory University School of Medicine.
Future directions in HIV basic science research The hunt for a cure.
KEY CONCEPT Some viral diseases can be prevented with vaccines.
HIV Cellular Pathogenesis III Benhur Lee, M.D.. Adult v. infant (IgG v. IgA) CTL response (MHC tetramers) p24 antigenimia Ab response Viral load.
1 EPIDEMIOLOGY 200B Methods II – Prediction and Validity Scott P. Layne, MD.
Future directions in HIV basic science research The hunt for a cure.
Disease transmission and control Defining Control objectives and strategies WHO/CSR Epidemiological Surveillance and Epidemic Response Unit Division of.
Why Do We Need To Understand the Structure of Viruses and How they Replicate?
Ebola Virus Nicole Fossas Biology 402. Causative Agent 1.Zaire 2.Sudan 3. Bundibugyo 4. Reston 5. Ivory Coast.
Monday, Aug. 18 Standard: Students will comprehend concepts related to health promotion to enhance health. EQ: What is the different causes of diseases?
Getting to Zero: Will San Francisco be the first city to succeed? Diane Havlir, MD, Professor of Medicine, UCSF, Chief HIV San Francisco General Hospital.
Infection and Disease Fungi Parasites Nosocomial infection Diagnosis of infectious disease.
IAS Members Meeting July 19th 2011 Achievements and learning over the past 30 years: what do we need next? Françoise BARRÉ-SINOUSSI Regulation of Retroviral.
1 Adherence to ARV Therapy and Resistance HAIVN Havard Medical School AIDS Initiative in Vietnam.
The Future of HIV/AIDS: The Road to a Cure. How HIV persists during therapy?  Ongoing viral replication occurs in subjects on suppressive HAART (TW Chun,
HUMAN IMMUNODEFICIENCY VIRUS AND ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS)
Evolution and transmission in HIV Steve Paterson Review; Rambaut 2004 Nature Reviews Genetics 5: ‘The causes and consequences of HIV evolution’
Meeting the Global Challenge ~ International workshop on antiviral drug resistance.
Large animal model Equine infectious anemia virus (EIAV) Visna-maedi virus (VMV) Caprine arthritis-encephalitis virus (CAEV)
VIROLOGY Claude MUVUNYI M.D, Ph.D. Head of Microbiology Unit/NRL RBC.
NIH HIV/AIDS Research Priorities
NIH HIV/AIDS Research Priorities
Lesson 4 Treatment for HIV / AIDS
Entry into care Failure to initiate timely HIV care after diagnosis is common ~75% of newly diagnosed link to care within 6-12 months Delayed entry into.
Non-ARV Based Interventions to Combat HIV/AIDS: New Insights and Initiatives Yves Lévy Inserm, VRI.
Jeopardy Game Hosted by PHDP Jamaica MODULE 4 Treatment Literacy.
Lesson 4 Treatment for HIV / AIDS
Outline.
KEY CONCEPT Some viral diseases can be prevented with vaccines.
Dr Paul T Francis, MD Community Medicine College of Medicine, Zawia
World Epidemiology. Are HIV and Other Chronic Diseases Models Applicable to Viral Hepatitis? Focus on HCV.
The Aging Liver in the Aging HIV and HCV Patients
Dr Paul T Francis, MD Community Medicine College of Medicine, Zawia
Virus Chapter 2 Lesson 1.
Engineering T Cells to Functionally Cure HIV-1 Infection
Trends in virological and clinical outcomes in individuals with HIV-1 infection and virological failure of drugs from three antiretroviral drug classes:
Infection Control for Medical Asepsis
Aim What happens when a bacteria or virus mutates?
Division of AIDS Office of the Director Workforce Operations,
Week 15 Vocab Definitions
Evolution and transmission in HIV
Immunopathogenesis of hepatitis C virus infection
Biology 4.3. Infection and Response.
Molecular virology and immunology of HIV infection
KEY CONCEPT Some viral diseases can be prevented with vaccines.
KEY CONCEPT Some viral diseases can be prevented with vaccines.
Diseases Caused by Bacteria and Viruses
KEY CONCEPT Some viral diseases can be prevented with vaccines.
Keep control: Elite and post-treatment controllers
Immunologic strategies for HIV-1 remission and eradication
Presentation transcript:

Track A Orientation Guido Silvestri, M.D. Track A Co-Chair

Key Issues in Basic AIDS Research  Virology:.New functions of viral gene products.Biology of reservoirs/latency.Drug resistance  Immunology.Correlates of protection (EC, VNP, EU, etc).Vaccines  Pathogenesis.Immune activation.Mucosal immune dysfunction.Pattern of infected cells.Natural non-pathogenic SIV infections

Monday July 18 th Reservoirs and Mechanisms of Disease Progression HIV and Co-Infections or Pathogenesis and management of long- term complications of ART Thirty years later: What we know and don’t know on how HIV causes AIDS Controversies on HIV cure research

Tuesday July 19 th New drugs and strategies or Preventative and therapeutic HIV vaccines Molecular virology and host restriction factors Antiviral immunity and transmission or Immune activation/inflammation & HIV disease NIH grantsmanship workshop or HIV-2: a model of attenuated infection

Wednesday July 20 th Towards an HIV cure: new strategies or Models of protection HIV Co-Infections: the axis of evil Emerging trends in HIV/HCV co-infection or Late Breakers A/B bridging or Towards and HIV cure: role of reservoirs Late Breaker A Rapporteurs and closing session